Journal: PLOS One
Article Title: Patient-derived organoids predict chemotherapy response of locally advanced gastric cancer
doi: 10.1371/journal.pone.0339416
Figure Lengend Snippet: (A) Schematic overview of GC PDOs experimental workflow: tissue isolation, organoid culture, histopathological evaluation, genomic analysis, in vitro drug sensitivity testing, and prediction of clinical response. (B) Representative bright-field images of GC-010 PDOs from day 0 to day 9 post-seeding in Matrigel. Scale bars, 100 µm. Similar growth patterns were observed across all 17 established PDO lines. (C) Bright-field images highlighting the morphological diversity among PDOs derived from SRCC (GC-014, GC-027) and non-SRCC (GC-010, GC-011). Scale bars, 100 µm. (D) Representative H&E staining images of GC PDOs and their corresponding parental tumors. GC-007 is SRCC and GC-025 is non-SRCC. Black arrow indicates signet ring cells; blue arrow indicates solid or cystic structures. Scale bars, 50 µm. (E) IHC staining of Ki67, CK7, CK20 and CDX2 in GC PDOs and their parental tumors from GC-007 and GC-025. GC PDOs faithfully recapitulated histologic features of their parental tumors. Scale bars, 50 µm. P, passage. D, day. GC, gastric cancer. PDOs, patient-derived organoids. SRCC, signet-ring cell carcinoma. Non-SRCC, non-signet-ring cell carcinoma.
Article Snippet: The primary antibodies used for IHC included Ki67 (clone SP6, 1:600 dilution, Servicebio, Wuhan, China), CK7 (clone 7D8G8, 1:600 dilution, Servicebio, Wuhan, China), CDX2 (clone 4H2A8, 1:1500 dilution, Servicebio, Wuhan, China), and CK20 (clone SP33, 1:1500 dilution, Servicebio, Wuhan, China).
Techniques: Isolation, In Vitro, Derivative Assay, Staining, Immunohistochemistry